BiopharmaceuticalsTechnical Analysis Guide

GILD Stock Analysis

Gilead Sciences, Inc.

💡 Quick Answer

Across 4 APEX technical signals, GILD is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-07-08. Run a live analysis to see the current composite score.

GILD is a value and growth hybrid. Its HIV franchise provides earnings stability while lenacapavir creates a genuine growth catalyst.

Lenacapavir Catalyst: Twice-yearly HIV preventionHIV Franchise Stability: Biktarvy market shareRSI Behavior: Value + catalyst 40-65 range

Gilead Sciences is a biopharmaceutical company with dominant positions in HIV treatment (Biktarvy, Descovy), hepatitis C, and a growing oncology portfolio (Trodelvy, Yescarta). Its HIV franchise generates exceptionally stable, high-margin recurring revenue as patients take daily medications for life. The lenacapavir HIV prevention injection (twice-yearly dosing) is the most significant HIV product in a decade and a potential blockbuster that could reshape HIV prevention globally.

LIVE CHART·GILD. DailyPowered by TradingView

Open GILD on TradingView ↗Affiliate link

Get live GILD signal analysis

APEX runs 8 signals on GILD in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze GILD Now →

Why Do Traders Watch GILD?

GILD is a value and growth hybrid. Its HIV franchise provides earnings stability while lenacapavir creates a genuine growth catalyst. ATR of 2-3% reflects its blend of defensive and growth characteristics. Post-earnings moves of 4-6% are typical. The stock is most sensitive to lenacapavir clinical and commercial updates, FDA decisions, and HIV prevention market share data from global health organizations.

Is GILD a Buy Right Now? Current Signal Readings

📊Lenacapavir CatalystTwice-yearly HIV prevention

Lenacapavir's PURPOSE trial demonstrated 100% HIV prevention efficacy in women in sub-Saharan Africa. A landmark result. Commercial rollout in high-income countries and WHO prequalification for low-income markets are the two catalysts that could add $3-5B in peak annual revenue. Each regulatory milestone moves GILD 5-10%.

📊HIV Franchise StabilityBiktarvy market share

Biktarvy holds ~55% of the HIV treatment market in the U.S.. An extraordinarily dominant position. Quarterly Biktarvy prescription data (available via IQVIA before earnings) provides high visibility into revenue. Market share stability above 50% confirms the business moat and supports the stock's defensive valuation floor.

📊RSI BehaviorValue + catalyst 40-65 range

GILD's RSI oscillates between defensive (40-45 on broader healthcare selloffs) and growth-driven spikes (65+ on pipeline catalysts). The transition from oversold RSI to catalyst momentum. When a lenacapavir milestone is approaching. Creates the highest-conviction GILD trade setup.

💊Oncology PipelineTrodelvy + cell therapy

Gilead's oncology portfolio. Trodelvy (TROP-2 ADC) and Yescarta (CAR-T). Is expanding into new cancer indications. Each Phase 3 trial readout in a new indication (particularly breast cancer and bladder cancer for Trodelvy) can move GILD 5-8% as investors reprice the oncology contribution to future revenue.

📋 GILD Key Stats for Traders

⚡ATR (14-day)2-3% of price

📦Avg daily volume~6-10 million shares

🎯Key metricLenacapavir rollout + Biktarvy share

📅Post-earnings move4-6% typical

🔗 Related Stocks

ABBV BMY MRNA AMGN

Run a live GILD analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze GILD Free →

Advanced charting for GILD on TradingView ↗

💬 Frequently Asked Questions. GILD

QIs GILD a good stock to buy right now?

AWhether GILD is a buy depends on its current technical positioning. GILD is a value and growth hybrid. Its HIV franchise provides earnings stability while lenacapavir creates a genuine growth catalyst. ATR of 2-3% reflects its blend of defensive and growth characteristics. Post-earnings moves of 4-6% are typical. The stock is most sensitive to lenacapavir clinical and commercial updates, FDA decisions, and HIV prevention market share data from global health organizations. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for GILD?

AThe four key signals for GILD are: Lenacapavir Catalyst (Twice-yearly HIV prevention). Lenacapavir's PURPOSE trial demonstrated 100% HIV prevention efficacy in women in sub-Saharan Africa. A landmark result. Commercial rollout in high-income countries and WHO prequalification for low-income markets are the two catalysts that could add $3-5B in peak annual revenue. Each regulatory milestone moves GILD 5-10%.. HIV Franchise Stability (Biktarvy market share). Biktarvy holds ~55% of the HIV treatment market in the U.S.. An extraordinarily dominant position. Quarterly Biktarvy prescription data (available via IQVIA before earnings) provides high visibility into revenue. Market share stability above 50% confirms the business moat and supports the stock's defensive valuation floor.. RSI Behavior (Value + catalyst 40-65 range). GILD's RSI oscillates between defensive (40-45 on broader healthcare selloffs) and growth-driven spikes (65+ on pipeline catalysts). The transition from oversold RSI to catalyst momentum. When a lenacapavir milestone is approaching. Creates the highest-conviction GILD trade setup.. Oncology Pipeline (Trodelvy + cell therapy). Gilead's oncology portfolio. Trodelvy (TROP-2 ADC) and Yescarta (CAR-T). Is expanding into new cancer indications. Each Phase 3 trial readout in a new indication (particularly breast cancer and bladder cancer for Trodelvy) can move GILD 5-8% as investors reprice the oncology contribution to future revenue.

QWhat is GILD's RSI telling traders right now?

AGILD's RSI oscillates between defensive (40-45 on broader healthcare selloffs) and growth-driven spikes (65+ on pipeline catalysts). The transition from oversold RSI to catalyst momentum. When a lenacapavir milestone is approaching. Creates the highest-conviction GILD trade setup. APEX scores GILD's RSI as part of its 8-factor composite signal. Updated daily.

QHow does GILD behave technically compared to other Biopharmaceuticals stocks?

AGILD is in the Biopharmaceuticals sector. Gilead Sciences is a biopharmaceutical company with dominant positions in HIV treatment (Biktarvy, Descovy), hepatitis C, and a growing oncology portfolio (Trodelvy, Yescarta). Its HIV franchise generates exceptionally stable, high-margin recurring revenue as patients take daily medications for life. The lenacapavir HIV prevention injection (twice-yearly dosing) is the most significant HIV product in a decade and a potential blockbuster that could reshape HIV prevention globally. Key stats: ATR (14-day): 2-3% of price, Avg daily volume: ~6-10 million shares, Key metric: Lenacapavir rollout + Biktarvy share, Post-earnings move: 4-6% typical.

QWhat MACD signals work best for GILD?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks GILD's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−